Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract: The present disclosure relates to an antibody against Aquaporin-4 (AQP4). These peptide-specific AQP4 antibodies play a role to create a NMO model and contribute for investigating the NMO disease mechanisms and developing the strategy of the treatment.
Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
December 19, 2023
Assignee:
DINGFU BIOTARGET CO., LTD.
Inventors:
Ting Xu, Yan Luan, Jianjian Peng, Kai Fu, Meng Zhao, Xiaoxiao Wang
Abstract: The present invention relates to treatment of cancer using agonist anti-MET antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer associated with chronic inflammation and/or gene mutations in the colon and in the gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis using agonist anti-MET antibodies.
Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
November 28, 2023
Assignee:
OncoResponse, Inc.
Inventors:
Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.
Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
November 21, 2023
Assignee:
Allergan, Inc.
Inventors:
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin, David W. Dodick
Abstract: The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.
Type:
Grant
Filed:
November 3, 2020
Date of Patent:
October 31, 2023
Assignee:
Code Biotherapeutics, Inc.
Inventors:
Robert Getts, Jessica Bowers, Mindy Ellen George-Weinstein, Jacquelyn Gerhart
Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
October 17, 2023
Assignee:
Board of Regents, The University of Texas System
Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.
Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
Type:
Grant
Filed:
March 3, 2022
Date of Patent:
October 17, 2023
Assignee:
AMBRX, INC.
Inventors:
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
Type:
Grant
Filed:
September 24, 2020
Date of Patent:
October 10, 2023
Inventors:
Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.
Abstract: The present invention provides compositions and methods for treating tumor-induced osteomalacia. The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
October 3, 2023
Assignees:
Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd.
Inventors:
Emil D. Kakkis, Javier San Martin, Tomohiro Sudo
Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.
Type:
Grant
Filed:
December 16, 2020
Date of Patent:
September 19, 2023
Assignee:
Board of Regents, The University of Texas System
Inventors:
Zhiqiang An, Ningyan Zhang, Philipp E. Scherer, Shangang Zhao
Abstract: The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.
Abstract: The present disclosure relates to a human FGF21 mutant with improved effectiveness and stability, preparation method and pharmaceutical composition comprising the mutant, and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia, or metabolic disorders.
Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib? that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
September 5, 2023
Assignee:
F. HOFFMAN-LA ROCHE AG
Inventors:
Elizabeth Booth, Virginia Montanini, John A. Hall, Jody Berry
Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
Type:
Grant
Filed:
March 17, 2021
Date of Patent:
August 29, 2023
Assignee:
ILDONG PHARM CO., LTD.
Inventors:
Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim